Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors
Paul Savage(Unknown), Morag Park(McGill University Health Centre), Constanza Martínez(McGill University Health Centre), Anie Monast(McGill University Health Centre), Jamil Asselah(McGill University), Adriana Aguilar‐Mahecha(Jewish General Hospital), Kevin Petrecca(McGill University Health Centre), Josiane Lafleur(Jewish General Hospital), Sarkis Meterissian(McGill University), Nathaniel Bouganim(McGill University Health Centre), Sohrab P. Shah(Memorial Sloan Kettering Cancer Center), Adrian Wan(University of British Columbia), Nicholas Bertos(McGill University), Atilla Ömeroğlu(McGill University), Matthew G. Annis(McGill University Health Centre), Valentina Muñoz-Ramos(McGill University Health Centre), Daniel Lai(Occupational Cancer Research Centre), Leah Liu(McGill University Health Centre), Mark Basik(Jewish General Hospital), Hellen Kuasne(McGill University Health Centre), Alain Pacis(Centre Hospitalier Universitaire Sainte-Justine), Samuel Aparício(BC Cancer Agency), Peter M. Siegel(L'Oréal (France)), Matthew Dankner(McGill University), Margarita Souleimanova(McGill University Health Centre), Hong Zhao(McGill University), Virginie Pilon(McGill University Health Centre)
Cited by 56
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The <i>GPR54</i> Gene as a Regulator of Puberty
|New England Journal of Medicine|2003|2.5k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k